University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

A joint research team from the LKS Faculty of Medicine (HKUMed) and the Faculty of Science at the University of Hong Kong has uncovered an unexpected interaction between chemotherapeutic agents and a ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

A new nanomedicine drug delivery system improves chemotherapy targeting for choriocarcinoma, shrinking tumors by 95% in mouse models. Researchers engineered polymersomes to enhance methotrexate (MTX) ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...